Due to the important role of GLP-1 on glucose and energy metabolism and its short half-life in the circulation, several degradation-resistant GLP-1r agonists have been developed and approved for the treatment of type 2 diabetes and more recently obesity (13). Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.